MGB Biopharma

About:

MGB Biopharma develops DNA minor groove binders-based anti-infective medicines.

Website: http://www.mgb-biopharma.com

Twitter/X: mgb_biopharma

Top Investors: Innovate UK, Archangels, Fund Twenty8, TRICAPITAL, Highlands and Islands Enterprise

Description:

MGB Biopharma Limited is a biopharmaceutical company established to develop a completely new class of anti-infective medicines based upon compounds which are DNA Minor Groove Binders (MGB) The company has an exceptionally experienced team from both pharma and biotech sectors and is dedicating its focus initially to the development of small molecules with specific antibacterial efffects against resistant bacteria By selecting a new class of antibacterial, the company believes the novel mode of action should prove to be very potent against bacteria as these target organisms will lack any inherent resistance, unlike that typically facing new drugs which are the result of modifications from existing classes of drugs used to treat bacterial infection

Total Funding Amount:

$18.4M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Snodland, Kent, United Kingdom

Founded Date:

2009-01-01

Contact Email:

enquiries(AT)mgb-biopharma.com

Founders:

Raymond Spencer

Number of Employees:

1-10

Last Funding Date:

2019-08-30

IPO Status:

Private

Industries:

© 2025 bioDAO.ai